GSK 3390107A

Drug Profile

GSK 3390107A

Alternative Names: cAd3 EBO Z; ChAd3-EBO-Z; GSK 3390107 A; Monovalent Ebola vaccine - NIAID/Okairos; Monovalent Ebola vaccine - Okairos/NIAID; Monovalent Ebola virus vaccine - NIAID/Okairos; Monovalent Ebola virus vaccine - Okairos/NIAID; Monovalent Zaire Ebola Chimpanzee Adenovirus vector vaccine -NIAID/Okairos; Monovalent Zaire Ebola Chimpanzee Adenovirus vector vaccine -Okairos/NIAID; VRC-EBOADC076-00-VP

Latest Information Update: 18 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Institute of Allergy and Infectious Diseases; Okairos
  • Developer National Institute of Allergy and Infectious Diseases; ReiThera; The Jenner Institute; University Hospital of Lausanne; University of Oxford
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Ebola virus infections

Most Recent Events

  • 11 Jul 2018 National Institute of Allergy and Infectious Diseases plans a phase I trial for Ebola virus infections in USA , (NCT03583606)
  • 17 Apr 2018 GSK 3390107A is still in phase I trials for Ebola virus infections in United Kingdom
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Ebola-virus-infections(Prevention, In volunteers) in United Kingdom (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top